Bone remodeling is a central event in the maintenance of skeletal tissue, and involves cycles of resorption followed by the formation of bone tissue. The activity of osteoclasts and osteoblasts during these cycles is tightly regulated by systemic and local factors coupling the action of these cells. Tartrate-resistant acid phosphatase (TRAP) is predominantly expressed in bone by osteoclasts but has also been detected in osteoblasts and osteocytes. Moreover, TRAP can stimulate the differentiation of mesenchymal lineage cells, i.e. progenitors of osteoblasts and adipocytes. In order to further explore the effects of TRAP on bone turnover, the structural and molecular phenotypes of osteoclasts and osteoblasts were assessed in TRAP-overexpressing transgenic mice. Transgenic mice of both sexes display increased cortical bone mineral content and density, which cannot be accounted for by decreased bone resorption since osteoclast numbers and resorptive activity do not differ from wild-type mice. Examination of the osteoblast phenotype revealed that markers of bone formation, i.e. procollagen type I N-terminal propeptides, and osteoblast lineage markers as well as the TRAP 1B mRNA transcript are increased in TRAP-overexpressing mice. Expression of the osteoclast-selective TRAP 1C mRNA is not increased in TRAP transgenic mice. Elevated expression of TRAP mRNA and protein were detected in osteoblasts, osteocytes and in the bone matrix of TRAP transgenic mice, suggesting that TRAP overexpression in osteoblast lineage cells is associated with increased cortical bone mineral content and density. The data presented here support the hypothesis that TRAP overexpression in the osteoblastic cell lineage stimulates the differentiation and/or activation of these cells.

Keywords:
Osteoclasts, Tartrate-resistant acid phosphatase, Osteoblasts, Bone resorption, Acid phosphatase type 5, Bone formation, Osteocytes, Mouse
1.
Andersson, G., A. Lindunger, B. Ek-Rylander (1989) Isolation and characterization of skeletal acid ATPase – a new osteoclast marker? Connect Tissue Res 20: 151–158.
2.
Angel, N.Z., N. Walsh, M.R. Forwood, M.C. Ostrowski, A.I. Cassady, D.A. Hume (2000) Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res 15: 103–110.
3.
Averill, B.A., J.C. Davis, S. Burman, T. Zirino, J. Sanders-Loehr, T.M. Loehr, J.T. Sage, P.G. Debrunner (1987) Spectroscopic and magnetic studies of the purple acid phosphatase from bovine spleen. J Am Chem Soc 109: 3760–3767.
4.
Baron, R. (2003) General principles of bone biology; in Favus, M. (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 5. Philadelphia, Lippincott Williams and Wilkins, pp 1–8.
5.
Bazer, F.W., D. Worthington-White, M.F. Fliss, S. Gross (1991) Uteroferrin: a progesterone-induced hematopoietic growth factor of uterine origin. Exp Hematol 19: 910–915.
6.
Bianco, P., P. Ballanti, E. Bonucci (1988) Tartrate-resistant acid phosphatase activity in rat osteoblasts and osteocytes. Calcif Tissue Int 43: 167–171.
7.
Bonucci, E., P. Mocetti, G. Silvestrini, P. Ballanti, S. Zalzal, M. Fortin, A. Nanci (2001) The osteoblastic phenotype in calcium-depleted and calcium-repleted rats: a structural and histomorphometric study. J Electron Microsc (Tokyo) 50: 333–347.
8.
Chang, M.K., L.J. Raggatt, K.A. Alexander, J.S. Kuliwaba, N.L. Fazzalari, K. Schroder, E.R. Maylin, V.M. Ripoll, D.A. Hume, A.R. Pettit (2008) Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol 181: 1232–1244.
9.
Del Fattore, A., R. Fornari, L. van Wesenbeeck, F. de Freitas, J.P. Timmermans, B. Peruzzi, A. Cappariello, N. Rucci, G. Spera, M.H. Helfrich, W. Van Hul, S. Migliaccio, A. Teti (2008) A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res 23: 380–391.
10.
de Souza Malaspina, T.S., C.X. dos Santos, A.P. Campanelli, F.R. Laurindo, M.C. Sogayar, J.M. Granjeiro (2008) Tartrate-resistant acid phosphatase activity and glutathione levels are modulated during hFOB 1.19 osteoblastic differentiation. J Mol Histol 39: 627–634.
11.
Ek-Rylander, B., G. Andersson (2010) Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistant acid phosphatase. Exp Cell Res 316: 443–451.
12.
Ek-Rylander, B., M. Flores, M. Wendel, D. Heinegard, G. Andersson (1994) Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 269: 14853–14856.
13.
Everts, V., W. Korper, K.A. Hoeben, I.D. Jansen, D. Bromme, K.B. Cleutjens, S. Heeneman, C. Peters, T. Reinheckel, P. Saftig, W. Beertsen (2006) Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21: 1399–1408.
14.
Favus, M. (2006) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 6. Washington, American Society for Bone and Mineral Research.
15.
Franzén, A., D. Heinegård (1985) Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232: 715–724.
16.
Funhoff, E.G., J. Ljusberg, Y. Wang, G. Andersson, B.A. Averill (2001) Mutational analysis of the interaction between active site residues and the loop region in mammalian purple acid phosphatases. Biochemistry 40: 11614–11622.
17.
Garnero, P., M. Ferreras, M.A. Karsdal, R. Nicamhlaoibh, J. Risteli, O. Borel, P. Qvist, P.D. Delmas, N.T. Foged, J.M. Delaisse (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18: 859–867.
18.
Halleen, J.M., S.R. Raisanen, S.L. Alatalo, H.K. Vaananen (2003) Potential function for the ROS-generating activity of TRACP. J Bone Miner Res 18: 1908–1911.
19.
Hollberg, K., K. Hultenby, A. Hayman, T. Cox, G. Andersson (2002) Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp Cell Res 279: 227–238.
20.
Hultenby, K., F.P. Reinholt, Å. Oldberg, D. Heinegård (1991) Ultrastructural immunolocalization of osteopontin in metaphyseal and cortical bone. Matrix 11: 206–213.
21.
Hunter, G.K., H.A. Goldberg (1993) Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci USA 90: 8562–8565.
22.
Hunter, G.K., B. Grohe, S. Jeffrey, J. O’Young, E.S. Sorensen, H.A. Goldberg (2009) Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin. Cells Tissues Organs 189: 44–50.
23.
Karsdal, M.A., T.J. Martin, J. Bollerslev, C. Christiansen, K. Henriksen (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22: 487–494.
24.
Karsdal, M.A., A.V. Neutzsky-Wulff, M.H. Dziegiel, C. Christiansen, K. Henriksen (2008) Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366: 483–488.
25.
Lång, P., G. Andersson (2005) Differential expression of monomeric and proteolytically processed forms of tartrate-resistant acid phosphatase in rat tissues. Cell Mol Life Sci 62: 905–918.
26.
Lång, P., V. van Harmelen, M. Ryden, M. Kaaman, P. Parini, C. Carneheim, A.I. Cassady, D.A. Hume, G. Andersson, P. Arner (2008) Monomeric tartrate resistant acid phosphatase induces insulin sensitive obesity. PLoS One 3: e1713.
27.
Ljusberg, J., B. Ek-Rylander, G. Andersson (1999) Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. Biochem J 343: 63–69.
28.
Ljusberg, J., Y. Wang, P. Lang, M. Norgard, R. Dodds, K. Hultenby, B. Ek-Rylander, G. Andersson (2005) Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 280: 28370–28381.
29.
Minkin, C. (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34: 285–290.
30.
Mocetti, P., P. Ballanti, S. Zalzal, G. Silvestrini, E. Bonucci, A. Nanci (2000) A histomorphometric, structural, and immunocytochemical study of the effects of diet-induced hypocalcemia on bone in growing rats. J Histochem Cytochem 48: 1059–1078.
31.
Nagy, T.R., A.L. Clair (2000) Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes Res 8: 392–398.
32.
Nakano, Y., S. Toyosawa, Y. Takano (2004) Eccentric localization of osteocytes expressing enzymatic activities, protein, and mRNA signals for type 5 tartrate-resistant acid phosphatase (TRAP). J Histochem Cytochem 52: 1475–1482.
33.
Nordahl, J., K. Hollberg, S. Mengarelli-Widholm, G. Andersson, F.P. Reinholt (2000) Morphological and functional features of clasts in low phosphate, vitamin D-deficiency rickets. Calcif Tissue Int 67: 400–407.
34.
Orlando, J.L., T. Zirino, B.J. Quirk, B.A. Averill (1993) Purification and properties of the native form of the purple acid phosphatase from bovine spleen. Biochemistry 32: 117–132.
35.
Perez-Amodio, S., I.M. Vogels, T. Schoenmaker, D.C. Jansen, S.L. Alatalo, J.M. Halleen, W. Beertsen, V. Everts (2005) Endogenous expression and endocytosis of tartrate-resistant acid phosphatase (TRACP) by osteoblast-like cells. Bone 36: 1065–1077.
36.
Perez-Amodio, S., D.C. Jansen, W. Tichelaar-Gutter, W. Beertsen, V. Everts (2006) Endocytosis of tartrate-resistant acid phosphatase by osteoblast-like cells is followed by inactivation of the enzyme. Calcif Tissue Int 78: 248–254.
37.
Puzas, J., T. Sheu, E. Schwarz, R. O´Keefe, R. Rosier (2001) An osteoblast phage display library identifies TRIP to have high affinity for TRAP. J Bone Miner Res 16(suppl 1): S164.
38.
Rissanen, J.P., M.I. Suominen, Z. Peng, J.M. Halleen (2008) Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82: 108–115.
39.
Robey, P.G., A.L. Boskey (2006) Extracellular matrix and biomineralisation of bone; in Murray, J.F. (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 6. Washington, American Society of Bone and Mineral Research.
40.
Sheu, T.J., E.M. Schwarz, D.A. Martinez, R.J. O’Keefe, R.N. Rosier, M.J. Zuscik, J.E. Puzas (2003) A phage display technique identifies a novel regulator of cell differentiation. J Biol Chem 278: 438–443.
41.
Takeda, S. (2008) Central control of bone remodelling. J Neuroendocrinol 20: 802–807.
42.
Walsh, N.C., M. Cahill, P. Carninci, J. Kawai, Y. Okazaki, Y. Hayashizaki, D.A. Hume, A.I. Cassady (2003) Multiple tissue-specific promoters control expression of the murine tartrate-resistant acid phosphatase gene. Gene 307: 111–123.
43.
Weibel, E. (1979) Stereological Methods, vol 1. Practical methods for biological morphometry. London, New York, Academic Press.
44.
Yamamoto, T., H. Nagai (1998) Ultrastructural localization of tartrate-resistant acid phosphatase activity in rat osteoblasts. J Electron Microsc (Tokyo) 47: 659–663.
45.
Yamaza, T., T. Goto, T. Kamiya, Y. Kobayashi, H. Sakai, T. Tanaka (1998) Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone 23: 499–509.
46.
Zenger, S., B. Ek-Rylander, G. Andersson (2010) Long bone osteoclasts display an augmented osteoclast phenotype compared to calvarial osteoclasts. Biochem Biophys Res Commun 394: 743–749.
47.
Zhang, Q., C. Wang, J. Tian, K. Li, H. Shou (2011) Identification of rice purple acid phosphatases related to phosphate starvation signalling. Plant Biol (Stuttg) 13: 7–15.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.